Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | TNIK | Q9UKE5 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2888874 | 0.94 | GRM5 (0.46) | GRM5PRMT5WDR77ROCK2ROCK1 | |
| SCHEMBL2887253 | 0.89 | EGLN1 (0.44) | GRM5EGLN1ROCK2ROCK1MAPK1 | |
| SCHEMBL2887054 | 0.85 | GRM5 (0.43) | GRM5PRMT5WDR77ROCK2ROCK1 | |
| SCHEMBL2891149 | 0.78 | ROCK2 (0.44) | GRM5PRMT5WDR77ROCK2ROCK1 | |
| SCHEMBL13207964 | 0.78 | PRMT5 (0.45) | GRM5PRMT5WDR77ROCK2ROCK1 | |
| SCHEMBL2891460 | 0.77 | OPRM1 (0.42) | — | |
| SCHEMBL2887263 | 0.72 | PRMT5 (0.41) | GRM5PRMT5WDR77ROCK2ROCK1 | |
| SCHEMBL2889094 | 0.69 | KDM4E (0.44) | GRM5 | |
| SCHEMBL16488375 | 0.68 | DDB1 (0.47) | GRM5MAPK1 | |
| SCHEMBL11985664 | 0.68 | PRMT5 (0.49) | PRMT5WDR77ROCK2ROCK1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2213675-B1 | PYRIDOOXAZEPINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-8329687-B2 | Pyridooxazepine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100286120-A1 | PYRIDOOXAZEPINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-2213675-A1 | PYRIDOOXAZEPINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286120-A1 | PYRIDOOXAZEPINE DERIVATIVE AND USE THEREOF | HTR2C, HTR2A, TPH2 | GRM5 117/4885PRMT5 1000/4885WDR77 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.